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Abstract The objective of this study is to assess patients’
satisfaction with migraine treatment with frovatriptan (F)
or zolmitriptan (Z), by preference questionnaire. 133 sub-
jects with a history of migraine with or without aura (IHS
criteria) were randomized to F 2.5 mg or Z 2.5 mg. The
study had a multicenter, randomized, double-blind, cross-
over design, with each of the two treatment periods lasting
no more than 3 months. At the end of the study, patients
were asked to assign preference to one of the treatments
(primary endpoint). The number of pain-free (PF) and
pain-relief (PR) episodes at 2 h, and number of recurrent
and sustained pain-free (SPF) episodes within 48 h were
the secondary study endpoints. Seventy-seven percent of
patients expressed a preference. Average score of prefer-
ence was 2.9 ± 1.3 (F) versus 3.0 ± 1.3 (Z; p = NS). Rate
of PF episodes at 2 h was 26% with F and 31% with Z
(p = NS). PR episodes at 2 h were 57% for F and 58% for
Z( p = NS). Rate of recurrence was 21 (F) and 24%
(Z; p = NS). Time to recurrence within 48 h was better for
F especially between 4 and 16 h (p\0.05). SPF episodes
were 18 (F) versus 22% (Z; p = NS). Drug-related adverse
events were signiﬁcantly (p\0.05) less under F (3 vs. 10).
In conclusion, our study suggests that F has a similar
efﬁcacy of Z, with some advantage as regards tolerability
and recurrence.
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Introduction
Triptans are generally considered as the most effective
acute treatment for migraine [1]. The therapeutic success of
sumatriptan, the parent drug of this class, in the treatment
of this neurological condition [2] has prompted the devel-
opment of other triptan compounds, trying to optimize
efﬁcacy and safety in migraine management.
Frovatriptan (F) is one of the newest triptans, developed
in order to provide a clinical potential for a long duration of
action and a low likelihood of side effects and drug inter-
actions [3].However,with the exceptionofone study versus
sumatriptan [4], there are presently no head-to-head ran-
domized trials comparing efﬁcacy and safety of F with that
of other triptans. For this reason, a study was setup to com-
pareefﬁcacyandsafetyofFversuszolmitriptan(Z),atriptan
widely employed as ﬁrst-line therapy for migraine [5].
The study has been designed to assess efﬁcacy by ana-
lyzing traditional migraine treatment endpoints and also by
considering patient’s preference to treatment [6].
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Study population and design
Male or female subjects, aged 18–65 years, with a current
history of migraine with or without aura, according to IHS
criteria, and with at least one migraine attack per month for
6 months prior to entering the study, were eligible for
participation in the study [7].
Patients with uncontrolled hypertension, cardiac, vas-
cular, liver and renal impairment, or any other severe or
disabling medical condition could not be enrolled. Indi-
viduals with history of alcohol or analgesic or psychotropic
drug abuse, known hypersensitivity to study drugs, previ-
ous inadequate response to at least two triptans, currently
using ergotamine (and its derivatives) or MAO-inhibitors,
or suffering from headaches that have been lasting for
[6 days, were excluded as well. Pregnant women, breast-
feeding mothers, and women with childbearing potential
having a positive or missing pregnancy test were not
eligible.
Written informed consent was obtained from all patients
prior to their inclusion in the study. The study was
approved by the Independent Institutional Review Boards
of the study centers.
The study had a multicenter, randomized, double-blind,
cross-over design, and included 14 Italian centers
(Appendix 1). Each patient received F 2.5 mg or Z 2.5 mg
in a randomized sequence. After treating three episodes of
migraine in not [3 months with the ﬁrst treatment, the
patient had to switch to the other treatment. After treating
three episodes of migraine in not [3 months with the
second treatment, each patient was asked to assign pref-
erence to one of the treatments according to a questionnaire
with a preference score graded from 0 to 5 on a 10-cm
scale.
Subjects were instructed to treat at least three migraine
episodes occurring in not[3 months and to come for the
second visit and to take one dose of study medication as
early as possible after the onset of migraine attack. If
insufﬁcient relief had been obtained after 2 h, patients were
allowed to take a second dose of study medication, with a
maximum daily intake of two doses. In case of insufﬁcient
relief 1 h after the intake of the second dose of the study
medication, patients were allowed to take a rescue medi-
cation (excluding other triptans, ergotamine or its
derivatives).
During the study use of concomitant medications,
occurrence of adverse events (from diary), blood pressure,
and heart rate were regularly checked, and a physical and
neurological examination performed. A headache diary
was dispensed with study medication.
Data analysis
The primary study endpoint was the between-treatment
comparison of the direction and average strength of pref-
erence at the end of the study, measured on a scale from 0
to 5. The hypothesis was that a superiority of one treatment
against the other had to occur in the presence of a differ-
ence of ?1.0 with a standard deviation of 2.375. Consid-
ering a two-tailed test with a 0.05 signiﬁcance level and an
80.7% power, the estimated number of patients to be ran-
domized was 120 (including a 25% of drop-outs), 60 for
each treatment group.
The intention-to-treat population (ITT, all patients
treating at least one attack in each treatment period and
completing the preference questionnaire) was the study
primary analysis population, while the per-protocol popu-
lation was the conﬁrmatory analysis.
Secondary study endpoints were quantiﬁed according to
IHS Guidelines [7] (1) pain-free (PF) episodes at 2 h
(absence of migraine 2 h after intake of one dose of study
drug and without any rescue medication), (2) recurrence
(migraine occurring within 48 h after a period without
migraine), (3) sustained pain-free (SPF) episodes within
48 h (migraine attack which is PF at 2 h, does not recur and
does not require the use of rescue medication or a second
study drug dose within 48 h), and (4) pain-relief (PR) epi-
sodes at 2 h (deﬁned as a decrease in migraine intensity
from severe or moderate to mild or none). Consistency of
recurrence, deﬁned as patients having at least two or three
recurrences over three attacks, was also assessed.
Safety analysis was applied to all randomized patients,
by calculating the incidence of adverse events and changes
in vital signs during the study.
Preference scores were compared between treatment
groups by analysis of variance, while logistic regression
analysis was used for testing the difference in the proportion
of patients with preference for one of the two drugs. Sec-
ondary endpoints were compared between groups by gen-
eralized estimatingequationanalysis.Thelevelof statistical
signiﬁcance was kept at 0.05 throughout the whole study.
Results
Baseline demographic and clinical data
A total of 133 patients were screened and randomized to
active treatment, of which 105 completed and 28 discon-
tinued the study.
The ITT population consisted of 107 patients (Table 1):
68 patients were valid for per-protocol analysis and 121 for
safety analysis.
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Seventy-seven percent of patients expressed a preference
for a triptan. Average preference score was 2.9 ± 1.3 with
F and 3.0 ± 1.3 with Z (p = NS). The average score was
3.2 ± 1.1 for F and 3.2 ± 1.2 for Z when values between 0
and 1 were considered as no preference and 5 as strong
preference. Most common reasons for preferring either
triptan were rapid activity (83% F vs. 72% Z), reduction of
headache severity (53 vs. 42%), and no side effects (40 vs.
40%). Additional preference results will be published in
detail elsewhere.
Secondary end-points
Thirty-four percent of patients preferred F while 43%
preferred Z (p = NS). Rate of PF episodes at 2 h (26 vs.
31%) was similar (p = NS) for F and Z, as well as the rate
of recurrent episodes (21 vs. 24%), SPF episodes (18 vs.
22%), and PR episodes at 2 h (57 vs. 58%) (Table 2). The
risk of recurrence over the 48 h was lower with F, espe-
cially between 4 and 16 h (p\0.05) (Fig. 1). Recurrence
of mild intensity attacks was lower for F (17%) than for Z
(37%) (p\0.05) as well as consistency of recurrence over
all the attacks (13% F vs. 20% Z; p\0.05).
Safety
Thirty-one adverse events were recorded (12 under F and
19 under Z). Side effects attributed to study treatment were
13 and occurred signiﬁcantly (p\0.05) more often in
Z- (n = 10) than in F-treated patients (n = 3); six events in
Z-treated patients versus none in F-treated patients has a
sever intensity (Table 3). No patient reported angina-like
symptoms (tachycardia, thoracic constriction, or pain) in
the F group versus four in the Z group (Table 3).
Discussion
This is the ﬁrst direct head-to-head comparative study of F
with another triptan, strictly applying IHS criteria for
deﬁnition of study endpoints. When using these traditional
endpoints, Z and F resulted in a similar efﬁcacy. This
difference did not seem to inﬂuence patient preference for
one drug or the other. Interestingly, the frequency of 48-h
SPF episodes was similar between the two triptans, though
a signiﬁcantly lower rate of recurrence was observed under
F in the ﬁrst 4–16 h from drug intake.
According to results of patient’s preference analysis, F
was chosen mainly because of the rapid speed of onset of
action (83% of patients) and the reduction in pain severity
(53% of patients): 40% of patients appreciated its good
tolerability.
Previous direct comparisons between F and Z are not
available. However, our results are in line with those of
previous studies based on Z [8–11]. As far as F is regarded,
Table 1 Demographic and clinical data of the patients of the ITT
population at the time of randomization
n = 107
Age (years, means ± SD) 38.3 ± 9.9
Females (n, %) 85 (79.4)
Height (cm, means ± SD) 165.9 ± 8.4
Weight (kg, means ± SD) 62.3 ± 12.6
Age at onset of migraine (years, means ± SD) 16.3 ± 6.5
Migraine attack duration[2 days (n, %) 17 (15.9)
MIDAS score (means ± SD) 22.1 ± 15.9
Migraine with aura (n, %) 16 (15.0)
No use of triptans in the previous 3 months (n, %) 30 (28.0)
Patients with moderate or severe attacks (n, %) 107 (100.0)
Data are shown as mean (±SD), or absolute (n) and relative
frequency (%)
Table 2 Result for the secondary study endpoints
ITT (n = 107) p PP (n = 68) p
FZ F Z
PF episodes at 2 h 80 (26) 94 (31) NS 49 (24) 65 (32) NS
Recurrent episodes 63 (21) 71 (24) NS 41 (20) 46 (23) NS
SPF episodes 56 (18) 66 (22) NS 37 (18) 47 (22) NS
PR episodes at 2 h 141 (57) 142 (58) NS 97 (57) 102 (58) NS
Data are shown for the ITT and the PP population and reported as
absolute (n) and relative (%) frequency. P refer to the statistical
signiﬁcance of the difference between the two treatment groups
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Fig. 1 Cumulative hazard of recurrence over the 48 h during
treatment with F (continuous line)o rZ( dashed line), in the 107
patients of ITT population. Asterisks refer to the statistical signiﬁ-
cance of the between-treatment difference (p\0.05)
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studies, showed a lower PR rate at 2 h with F as respect to
our study (38–40 vs. 57%) [3]. The additional ﬁnding of
our study is that proportion of PF episodes at 2 h was much
higher than that observed in previous placebo-controlled
studies (26 vs. 9–14%) [10].
F showed a similar efﬁcacy and patient’s preference,
while appeared to be safer than Z, with a signiﬁcantly
lower rate of drug-related adverse events.
In conclusion, our multicenter, randomized, double-
blind trial, supports the validity of the patient preference
approach for the evaluation of migraine treatment, and
suggests that, in spite of a similar efﬁcacy, on the long-
term, F may have some advantage on Z in terms of safety.
Acknowledgments The present study was supported by Istituto
Lusofarmaco d’Italia.
Conﬂict of interest All authors have occasionally served as scien-
tiﬁc consultants for manufacturers of frovatriptan or zolmitriptan.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
Appendix 1: list of study sites
Coordinator: G. Bussone (Milano).
Investigators: M. Gionco (Torino), A. Aguggia (Novi
Ligure), B. Colombo (Milano), M. Turla (Esine), F. Perini
(Vicenza), A. Ganga (Sassari), E. Agostoni (Lecco),
C. Narbone (Messina), A. Moschiano (Merate), M. Vacca
(Cagliari), M. Bartolini (Ancona), A. Ambrosini (Pozzilli),
R. De Simone (Napoli), V. Petretta, F. D’Onofrio (Avel-
lino), G. Reggiardo (Biostatistical Unit, Mediservice, Mi-
lano), F. Sacchi (Clinical Unit, Mediservice, Milano).
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Table 3 Distribution of absolute numbers of drug-related adverse events between the two treatment groups, in the 121 patients of the safety
analysis
F( n = 121) Z (n = 121) All (n = 121)
Intensity Intensity
Mild Moderate Severe Mild Moderate Severe
Asthenia – 2 – – 1 – 3
Nausea or vomiting – – – – – 1 1
Palpitation or tachycardia – – – – – 1 1
Muscular or bone pain – – – – 1 – 1
Thoracic constriction or pain – – – – – 2 1
Vertigo – – – – – 1 1
Occipital burning sensation – – – – 1 – 1
Sensation of being dazed – – – – – 1 1
Other 1 – – 1 – – 3
Total adverse events 3 10 13
Total patients (%) 2 (1.7) 5 (4.1) 7 (5.8)
Drug-related side effects occurred signiﬁcantly more often in Z-treated patients (p\0.05)
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